Menu Search
Equities

PMD Device Solutions AB

8T00:STU

PMD Device Solutions AB

Actions
  • Price (EUR)0.124
  • Today's Change-0.055 / -30.73%
  • Shares traded0.00
  • 1 Year change-80.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.

  • Revenue in SEK (TTM)51.91m
  • Net income in SEK-43.42m
  • Incorporated2003
  • Employees37.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		PMDS:STO since
announced		Transaction
value
Coala-Life IncDeal completed09 Apr 202409 Apr 2024Deal completed-84.89%--
PMD Device Solutions ABDeal completed29 Nov 202329 Nov 2023Deal completed-79.06%13.23m
Data delayed at least 15 minutes, as of Nov 14 2024 12:48 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.